Skip to main content
Marcel Nijland
dr.

I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.

Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA
Published in: Journal of Hematology and Oncology
Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic PTLD after solid organ transplantation in this multi-center observational cohort study. We used low-coverage whole genome sequencing (lcWGS) to detect copy number variations (CNVs) and targeted next-generation sequencing (NGS) to identify...
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
Published in: Blood cancer journal
Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor outcomes. Clinical characteristics associated with transformation risk and outcome after transformation are largely unknown due to scarcity of data. In this population-based study, competing risk analyses were performed to elucidate clinical characteristics associated with developing transformation among 1793 MZL patients using the Netherlands Cancer Registry. Cox regression analyses were performed to elucidate clinical characteristics associated with risk of relapse and mortality after transformation. Transformation occurred in 75 (4%) out of 1793 MZL...
Johanna A A Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H Tonino, Joost S P Vermaat, Martine E D Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J Plattel, Mirian Brink, Marcel Nijland
Zoonotic Transmission of Vaccine-Derived Bordetella bronchiseptica.
Published in: Open Forum Infectious Diseases
We describe a unique case of a 43-year-old-female with a Bordetella bronchiseptica infection caused by zoonotic transmission following vaccination of her dog. With this report, we want to raise awareness of potential zoonotic transmission of live attenuated vaccines from animals to patients with impaired immunity.
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 – 17 June, 2023
V. de Jonge, J. Bult, D. Karssing, M. Nijland, M. Chamuleau, M. Brink
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 – 17 June, 2023
F. O. Meeuwes, M. Brink, W. J. Plattel, J. S.P. Vermaat, M. J. Kersten, M. Wondergem, O. Visser, M. W.M. van der Poel, R. Oostvogels, F. J.S.H. Woei-A-Jin, L. H. Böhmer, G. A. Huls, M. Nijland